JNJ news and market impact
Real-time Johnson & Johnson news affecting stock and options prices
Latest JNJ news
FDA Commissioner Marty Makary resigned following mounting backlash from pharmaceutical companies, physicians, and patient groups over regulatory decisions and faster vape approvals.
FDA Commissioner Marty Makary resigned following mounting backlash from pharmaceutical companies, physicians, and patient groups over regulatory decisions and faster vape approvals. Acting Commissioner Kyle Diamantas will temporarily take over the agency. The resignation ends a tenure marked by internal dysfunction and leadership turmoil.
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
The Trump White House claims negotiated agreements with drugmakers could save the U.S. economy $529 billion over 10 years through cost reductions.
The Trump White House claims negotiated agreements with drugmakers could save the U.S. economy $529 billion over 10 years through cost reductions. The deals represent a policy shift toward pharmaceutical price negotiation and potential regulatory relief.
Eaton delivered strong Q1 earnings with revenue of $7.45B (+17% YoY) and EPS of $2.81, both beating consensus, driven by AI data center demand for power management solutions.
Eaton delivered strong Q1 earnings with revenue of $7.45B (+17% YoY) and EPS of $2.81, both beating consensus, driven by AI data center demand for power management solutions. Despite the beat, the stock sold off 2%+ on Tuesday, prompting CNBC's investment club to upgrade the stock to buy and raise the price target to $450 from $425.
How news affects JNJ
Johnson & Johnson (JNJ) is sensitive to: drug approvals, litigation, earnings, FDA regulation.Diversified pharma and medical devices — post consumer health spinoff.
Related tickers
Get JNJ alerts before the market moves
AI-powered news filtering. Only what matters to your positions.
Start free trialFrequently asked questions
What is moving JNJ today?
FDA Commissioner Marty Makary resigned following mounting backlash from pharmaceutical companies, physicians, and patient groups over regulatory decisions and faster vape approvals.
How do I get JNJ news alerts?
Sign up for Tradar and add JNJ to your watchlist. You'll get push notifications for high-impact news within seconds.